Search
South Australian families with babies showing early social and communication differences will be among the first to benefit from a nation-leading early support program, as The Kids Research Institute Australia’s Inklings Program officially launches in South Australia.
Professor Andrew Whitehouse, the Angela Wright Bennett Professor of Autism Research and CliniKids Director, has been appointed Deputy Director (Research) at The Kids Research Institute Australia.
A world-first program for babies with delays in their social and communication skills has been launched in Western Australia, thanks to support from the National Disability Insurance Agency (NDIA).
Autism researcher Professor Andrew Whitehouse has been named this year’s Western Australian of the Year in the HBF Professions category.
New research evaluating the potential cost savings of a therapy for babies displaying early autism signs has predicted a three dollar return to Australia’s National Disability Insurance Scheme (NDIS) for every dollar invested in therapy.
Professor Andrew Whitehouse, who has helped transform clinical support for children on the autism spectrum in Australia, is nominated for WA's 2023 Australian of the Year.
Professor Andrew Whitehouse has been inducted as the youngest-ever Fellow to the Australian Academy of Health and Medical Sciences.
CliniKids is the first clinical service of The Kids Research Institute Australia, providing autism therapies and supports for young children.
CliniKids is a not-for-profit centre integrating world-class research with a clinical service for children with developmental delay and/or autism, and their families. It is the first of its kind for autism in Australia.
Our team of world-class researchers and exceptional clinicians work in collaboration to provide children access to the very best evidence-based therapies and programs.
Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Knowledge gaps regarding human immunity to Streptococcus pyogenes have impeded vaccine development. To address these gaps and evaluate vaccine candidates, we established a human challenge model of S. pyogenes pharyngitis. Here, we analyse antibody responses in serum and saliva against 19 antigens to identify characteristics distinguishing 19 participants who developed pharyngitis and 6 who did not.
Scabies is one of the world’s most prevalent diseases, with approximately 147 million cases at any one time and an estimated annual incidence of 455 million new episodes. Although Group A streptococcal (GAS) pharyngitis has long been implicated in the pathogenesis of acute rheumatic fever (ARF) and subsequent rheumatic heart disease (RHD), impetigo caused by GAS has recently been postulated as a link between scabies and the pathogenesis of ARF.
Group A streptococcus (GAS) infections, such as pharyngitis and impetigo, can lead to rheumatic fever and rheumatic heart disease (RHD). Australian Aboriginal and Torres Strait Islander populations experience high rates of RHD and GAS skin infection, yet rates of GAS pharyngitis are unclear.
Streptococcus dysgalactiae subspecies equisimilis and Streptococcus pyogenes share skin and throat niches with extensive genomic homology and horizontal gene transfer possibly underlying shared disease phenotypes.
Streptococcus pyogenes, also known as group A streptococcus (StrepA), is a bacterium that causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and post-infection immune sequelae such as rheumatic fever and rheumatic heart disease. StrepA infections cause some of the highest burden of disease and death in mostly young populations in low-resource settings. Despite decades of effort, there is still no licensed StrepA vaccine, which if developed, could be a cost-effective way to reduce the incidence of disease.